Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial.
Treatment of anaemia in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction has traditionally focused on erythropoietin-stimulating agents. However, recent studies have shown that treatment with intravenous (IV) iron can improve the symptoms and quality of life in patients with CHF and iron deficiency (ID), with or without anaemia. The management of ID is becoming an important therapeutic target in patients with CHF, and in this article, we will review iron metabolism in the context of anaemia and heart failure. We will also focus on the importance of diagnosing and treating ID, preferably with IV iron preparations, in patients with CHF.
González-Costello
José
J
Heart Failure and Cardiac Transplant Unit, Department of Cardiology, Hospital Universitari de Bellvitge, Institut d'Investigació Biomédica de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain. jgcostello@hotmail.com
Comín-Colet
Josep
J
D018798:Anemia, Iron-Deficiency / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy; D000818:Animals; D005293:Ferritins / Q000097:blood; D006333:Heart Failure / Q000453:epidemiology* / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism; D000090463:Iron Deficiencies; D013318:Stroke Volume; D014168:Transferrin / Q000032:analysis
D014168:Transferrin; D005293:Ferritins; D007501:Iron